Clinical Trial Update: A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Boehringer Ingelheim's BI 1819479 for improving lung function in idiopathic pulmonary fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• BI 1819479

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED